TBPH
Theravance Biopharma, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Sep 23. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 9 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate $0.200 → $0.200 over 90 days.
- Short sellersSTEADY
Short interest +4.2% to 1.69M shares. 4.5 days to cover, ≈3.3% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MACKENZIE FINANCIAL CORP | EXIT | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| MACKENZIE FINANCIAL CORP | DOUBLED | $16.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jul 2026| Date | Firm | Rating |
|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Jun 29, 2026 | Jones Trading DOWNGRADE | Hold |
| Jun 29, 2026 | BTIG DOWNGRADE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Sep 23, 2026 | OTHER | |
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Sep 23, 2026 | TO ISSUER | 124,414 sh |
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Sep 23, 2026 | TO ISSUER | 89,062 sh |
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Sep 23, 2026 | TO ISSUER | 150,000 sh |
Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Sep 23, 2026 | TO ISSUER | 223,917 sh |
Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Sep 23, 2026 | TO ISSUER | 107,812 sh |
Miller Aine SVP, DEV & HEAD OF IRE OFFICE Sep 23, 2026 | TO ISSUER | 93,108 sh |
Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Sep 23, 2026 | TO ISSUER | 23,439 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.20 | $0.20–$0.20 | +0.0% | $20.6M |
| Next Q | -$0.08 | -$0.08–-$0.08 | +0.0% | $22.1M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $1.27 | $0.80–$1.75 | +59.4% | $84.8M |
Short side
FINRA· Sep 15, 2026SecBot reports
12 filings · 4 bullish · 3 bearish · 1 mixed · 4 neutral- NEUTRAL SC 13G/ANov 16, 2026
Madison Avenue Partners, LP filed a Schedule 13G/A disclosing that as of September 23, 2026, following the merger of Theravance Biopharma with Zymeworks Inc., its affiliated funds no longer beneficially own any ordinary shares of Theravance Biopharma. The stake was converted to $17.00 per share…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 15-12GOct 5, 2026
Theravance Biopharma filed a Form 15 to terminate its SEC registration and suspend reporting…
With only one holder of record and a prior delisting notice, the company has effectively completed a going-private transaction. Monitor for any subsequent OTC trading updates or a final merger…
- NEUTRAL SC 13D/ASep 25, 2026
Weiss Asset Management LP filed a Schedule 13D/A reporting that its stake in Theravance Biopharma…
The merger with Zymeworks Inc. has closed, and the activist has exited. Monitor post-merger integration and any potential dissenting shareholder appraisal rights or litigation, though none are…
- BEARISH 25-NSESep 23, 2026
The Nasdaq Stock Market LLC filed a Form 25-NSE to report the removal from listing and…
The delisting under Rule 12d2-2(a)(3) indicates the securities have been fully redeemed, retired, or the company has been acquired. Shareholders should expect no further trading on Nasdaq; any…
All TBPH filing & press-release reports (12)
- SC 13G/A reportNov 16, 2026
- 15-12G reportOct 5, 2026
- SC 13D/A reportSep 25, 2026
- 25-NSE reportSep 23, 2026
- DEFA14A reportAug 25, 2026
- DEFM14A reportAug 21, 2026
- PREM14A reportAug 11, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 29, 2026
- 8-K reportJun 23, 2026
- 8-K reportMay 7, 2026
- 8-K reportMar 3, 2026